baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Morgan Stanley Knock-Out Argenx S.../ DE000MG14JK8 /

2024-07-31 8:56:48 PM	Chg.+0.94	Bid10:00:34 PM	Ask10:00:34 PM	Underlying	Strike price	Expiration date	Option type
26.42EUR	+3.69%	- Bid Size: -	- Ask Size: -	-	215.7639 EUR	2078-12-31	Call

GlobeNewswire 06-25 argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...

GlobeNewswire 06-21 argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...

GlobeNewswire 06-17 argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...

GlobeNewswire 06-13 Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

GlobeNewswire 06-04 argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire 05-09 argenx Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 05-07 argenx announces results of Annual General Meeting of Shareholders

GlobeNewswire 05-07 argenx to Present at BofA Securities 2024 Health Care Conference

GlobeNewswire 05-02 argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

GlobeNewswire 04-16 argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...

GlobeNewswire 03-27 argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

GlobeNewswire 03-26 argenx Announces Annual General Meeting of Shareholders on May 7, 2024

GlobeNewswire 03-26 argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...

GlobeNewswire 03-07 argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...

GlobeNewswire 02-29 argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire 02-26 argenx to Present at Upcoming Investor Conferences

GlobeNewswire 02-22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...

GlobeNewswire 02-20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...

GlobeNewswire 02-14 Genmab Publishes 2023 Annual Report

GlobeNewswire 01-18 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...

GlobeNewswire 01-08 argenx Highlights 2024 Strategic Priorities

GlobeNewswire 01-02 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire 2023-12-07 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...

GlobeNewswire 2023-11-28 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...

GlobeNewswire 2023-11-16 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...

Morgan Stanley Knock-Out Argenx S.../ DE000MG14JK8 /

If you wish to receive reply to your feedback, please provide your email address.